Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1 - PubMed (original) (raw)
Review
. 2004 Nov;28(11):1357-64.
doi: 10.1038/sj.ijo.0802778.
Affiliations
- PMID: 15356668
- DOI: 10.1038/sj.ijo.0802778
Review
Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
T Skurk et al. Int J Obes Relat Metab Disord. 2004 Nov.
Abstract
Obesity is the central promoter of the metabolic syndrome which also includes disturbed fibrinolysis in addition to hypertension, dyslipidaemia and impaired glucose tolerance/type 2 diabetes mellitus. Plasminogen activator inhibitor-1 (PAI-1) is the most important endogenous inhibitor of tissue plasminogen activator and uro-plasminogen activator, and is a main determinant of fibrinolytic activity. There is now compelling evidence that obesity and, in particular, an abdominal type of body fat distribution are associated with elevated PAI-1 antigen and activity levels. Recent studies established that PAI-1 is expressed in adipose tissue. The greater the fat cell size and the adipose tissue mass, the greater is the contribution of adipose production to circulating PAI-1. Experimental data show that visceral adipose tissue has a higher capacity to produce PAI-1 than subcutaneous adipose tissue. Studies in human adipocytes indicate that PAI-1 synthesis is upregulated by insulin, glucocorticoids, angiotensin II, some fatty acids and, most potently, by cytokines such as tumour necrosis factor-alpha and transforming growth factor-beta, whereas catecholamines reduce PAI-1 production. Interestingly, pharmacological agents such as thiazolidinediones, metformin and AT(1)-receptor antagonists were found to reduce adipose expression of PAI-1. In addition, weight loss by dietary restriction or comprehensive lifestyle modification is effective in lowering PAI-1 plasma levels. In conclusion, impaired fibrinolysis in obesity is probably also due to an increased expression of PAI-1 in adipose tissue. An altered function of the endocrine system and an impaired auto-/paracrine function at the fat cell levels may mediate this disturbance of the fibrinolytic system and thereby increase the risk for cardiovascular disease..
Similar articles
- Fat cell function and fibrinolysis.
Alessi MC, Morange P, Juhan-Vague I. Alessi MC, et al. Horm Metab Res. 2000 Nov-Dec;32(11-12):504-8. doi: 10.1055/s-2007-978677. Horm Metab Res. 2000. PMID: 11246816 Review. - Stimulated in vivo synthesis of plasminogen activator inhibitor-1 in human adipose tissue.
Ekström M, Liska J, Eriksson P, Sverremark-Ekström E, Tornvall P. Ekström M, et al. Thromb Haemost. 2012 Sep;108(3):485-92. doi: 10.1160/TH11-11-0822. Epub 2012 Jun 28. Thromb Haemost. 2012. PMID: 22740034 - Visceral fat as a determinant of fibrinolysis and hemostasis.
Mertens I, Van Gaal LF. Mertens I, et al. Semin Vasc Med. 2005 Feb;5(1):48-55. doi: 10.1055/s-2005-871741. Semin Vasc Med. 2005. PMID: 15968580 Review. - Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
Mertens I, Van der Planken M, Corthouts B, Wauters M, Peiffer F, De Leeuw I, Van Gaal L. Mertens I, et al. Horm Metab Res. 2001 Oct;33(10):602-7. doi: 10.1055/s-2001-17907. Horm Metab Res. 2001. PMID: 11607880 - Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.
He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B. He G, et al. Horm Metab Res. 2003 Jan;35(1):18-23. doi: 10.1055/s-2003-38386. Horm Metab Res. 2003. PMID: 12669266
Cited by
- Early Effects of Laparoscopic Sleeve Gastrectomy and Laparoscopic One-Anastomosis Gastric Bypass on Portal Venous Flow: a Prospective Cohort Study.
Osman AMA, Helmy AS, Mikhail S, AlAyat AA, Serour DK, Ibrahim MY. Osman AMA, et al. Obes Surg. 2021 Jun;31(6):2410-2418. doi: 10.1007/s11695-021-05267-3. Epub 2021 Mar 4. Obes Surg. 2021. PMID: 33660156 - Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity.
Jeon H, Kim JH, Kim JH, Lee WH, Lee MS, Suk K. Jeon H, et al. J Neuroinflammation. 2012 Jun 29;9:149. doi: 10.1186/1742-2094-9-149. J Neuroinflammation. 2012. PMID: 22747686 Free PMC article. - A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.
Morrow GB, Whyte CS, Mutch NJ. Morrow GB, et al. Front Cardiovasc Med. 2021 Apr 16;8:653655. doi: 10.3389/fcvm.2021.653655. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33937363 Free PMC article. Review. - Exploring the Therapeutic Potential of Apigenin in Obesity-Associated Fibrinolytic Dysfunction: Insights From an Animal Study.
Qadi HH, Bendary MA, Almaghrabi SY, Zaher MAF, Karami MM, Alsehli AM, Babateen O, Arbaeen AF, Burzangi AS, Bazuhair MA. Qadi HH, et al. Cureus. 2023 Jun 25;15(6):e40943. doi: 10.7759/cureus.40943. eCollection 2023 Jun. Cureus. 2023. PMID: 37503477 Free PMC article. - Adipose Tissue Hypoxia in Obesity: Clinical Reappraisal of Hypoxia Hypothesis.
Engin A. Engin A. Adv Exp Med Biol. 2024;1460:329-356. doi: 10.1007/978-3-031-63657-8_11. Adv Exp Med Biol. 2024. PMID: 39287857 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous